Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting

American Journal of Ophthalmology

Volumn 172, Issue , 2016, Pages 51-57

  Patrao, Namritha V ^a   Antao, Sheelah ^a   Egan, Catherine ^a   Omar, Amer ^a   Hamilton, Robin ^a,b   Hykin, Philip G ^a   Sivaprasad, Sobha ^a,b   Rajendram, Ranjan ^a,b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

AGED; ARTICLE; CATARACT; CENTRAL RETINA ARTERY OCCLUSION; CONGENITAL CORNEA DYSTROPHY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FEMALE; HUMAN; LOW LEVEL LASER THERAPY; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY; COMPLICATION; DIABETIC RETINOPATHY; DIAGNOSTIC IMAGING; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA LUTEA; TIME FACTOR;

AGED; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; RANIBIZUMAB; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ACUITY;

EID: 84993960907     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2016.09.002     Document Type: Article

References (19)

1. 1 Keenan, T.D., Johnston, R.L., Donachie, P.H., Sparrow, J.M., Stratton, I.M., Scanlon, P., United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of center-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye (Lond) 27:12 (2013), 1397–1404.
2. 2 Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:1 (2010), 4–14.
3. 3 Diabetic Retinopathy Clinical Research Network, A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115:9 (2008), 1447–1459.
4. 4 Elman, M.J., Aiello, L.P., Beck, R.W., et al. Diabetic Retinopathy Clinical Research Network. randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:6 (2010), 1064–1077.
5. 5 Mitchell, P., Bandello, F., Schmidt-Erfurth, U., et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:4 (2011), 615–625.
6. 6 Pearce, I., Banerjee, S., Burton, B.J., et al. Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT study. Ophthalmology 122:9 (2015), 1811–1819.
7. 7 Nguyen, Q.D., Shah, S.M., Khwaja, A.A., Channa, R., Hatef, E., Do, D.V., et al. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 117:11 (2010), 2146–2151.
8. 8 Massin, P., Bandello, F., Garweg, J.G., Hansen, L.L., Harding, S.P., Larsen, M., et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:11 (2010), 2399–2405.
9. 9 Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:4 (2012), 789–801.
10. 10 Schmidt-Erfurth, U., Lang, G.E., Holz, F.G., et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121:5 (2014), 1045–1053.
11. 11 Michaelides, M., Kaines, A., Hamilton, R.D., et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117:6 (2010), 1078–1086e2.
12. 12 Ishibashi, T., Li, X., Koh, A., et al. REVEAL Study Group. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology 122:7 (2015), 1402–1415.
13. 13 Korobelnik, J.F., Do, D.V., Schmidt-Erfurth, U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:11 (2014), 2247–2254.
14. 14 Wells, J.A., Glassman, A.R., Ayala, A.R., et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med 372:13 (2015), 1193–1203.
15. 15 Lammer, J., Scholda, C., Prünte, C., Benesch, T., Schmidt-Erfurth, U., Bolz, M., Retinal thickness and volume measurements in diabetic macular edema: a comparison of four optical coherence tomography systems. Retina 31:1 (2011), 48–55.
16. 16 Gregori, N.Z., Feuer, W., Rosenfeld, P.J., Novel method for analyzing Snellen visual acuity measurements. Retina 30:7 (2010), 1046–1050.
17. 17 Brynskov, T., Laugesen, C., Sørensen, T., Intravitreal ranibizumab for diabetic macular oedema: 1-year experiences in a clinical setting. Acta Ophthalmol 91:3 (2013), 243–244.
18. 18 Menchini, U., Bandello, F., De Angelis, V., et al. Ranibizumab for visual impairment due to diabetic macular edema: real-world evidence in the Italian population (PRIDE Study). J Ophthalmol, 2015, 2015, 324841.
19. 19 Dugel, P.U., Layton, A., Varma, R.B., Diabetic macular edema diagnosis and treatment in the real world: an analysis of Medicare claims data (2008-2010). Ophthalmic Surg Lasers Imaging Retina 47 (2016), 258–267.